ZANTAC Injection Gets FDA Blessing Despite Chemical Concerns
Published Date: 12/12/2025
Notice
Summary
The FDA has decided that ZANTAC injection (25 mg/mL) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they meet safety rules, especially about tiny impurities. Patients and drug makers can breathe easy knowing ZANTAC injection stays available under strict quality checks.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Generics Can Still Be Approved
The FDA says it will continue to approve abbreviated new drug applications (ANDAs) that refer to ZANTAC (ranitidine HCl) injection, equivalent to 25 mg base/mL, as long as the applicants meet all legal and regulatory requirements. That includes satisfying any applicable acceptable intake limit for nitrosamine impurities before approval is granted.
Existing ANDA Approvals Protected
FDA will not begin procedures to withdraw approval of any approved ANDAs that refer to ZANTAC (ranitidine HCl) injection, EQ 25 mg base/mL. The listed product remains in the Orange Book's Discontinued Drug Product List, but existing ANDA approvals that reference it will not be subject to withdrawal procedures based on safety or effectiveness.
Patient Access to ZANTAC Injection
If you are a patient who needs ZANTAC (ranitidine HCl) injection, equivalent to 25 mg base/mL, the FDA determined the product was not withdrawn for safety or effectiveness reasons so long as it can be made to meet nitrosamine impurity limits. That means the drug can remain available through generic approvals if manufacturers meet those safety limits.
Nitrosamine Limits Required for Approval
FDA's determination is conditional: the drug must be manufactured or formulated in a way that satisfies any applicable acceptable intake limit for nitrosamine impurities before ANDAs can be approved. Applicants must meet those nitrosamine intake limits and other regulatory requirements for approval to proceed.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-22675 — National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a virtual meeting on January 27, 2026, to discuss research updates and review grant applications. Anyone interested can watch the open session online, but the grant review part is private to protect sensitive info. This meeting affects researchers and organizations seeking funding and helps decide which projects get support.
Next: 2025-22677 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V COCONUT MONKEY
The Maritime Administration is checking if the foreign-built small passenger vessel M/V COCONUT MONKEY can be used for U.S. coastwise trade without hurting American boat builders or businesses. They’re asking for public comments by January 12, 2026, to help decide. If approved, this could open doors for new passenger services but won’t cost taxpayers anything right now.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in